Corpus ID: 31177799

BP-897 Bioprojet.

  title={BP-897 Bioprojet.},
  author={A. Preti},
  journal={Current opinion in investigational drugs},
  volume={1 1},
  • A. Preti
  • Published 2000
  • Medicine
  • Current opinion in investigational drugs
BP-897 is a dopamine D3 receptor agonist which is under development by Bioprojet for the potential treatment of drug craving and vulnerability to relapse that are elicited by drug-associated environmental stimuli; it is undergoing phase I trials [318397,334036,340721]. Preclinical investigations were carried out by Cambridge University and INSERM [295680]. BP-897 functions as a partial agonist in vitro and as either an agonist or an antagonist in vivo. It inhibits cocaine-seeking behavior that… Expand
Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
An important role for D3 receptors in mediating the addictive properties of cocaine is suggested and blockade of dopamine D3receptors may constitute a new and useful target for prospective pharmacotherapies for cocaine addiction. Expand
Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.
Preclinical findings using animal models of drug-seeking behaviors confirm that D3 antagonists have a promising profile to treat drug addiction across drugs of abuse type and support further exploration of D3 ligands to treating drug addiction. Expand
Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats
The mesolimic DA D3 receptor plays an important role in mediating stress-induced reinstatement of cocaine-seeking behavior and is investigated in rats allowed to self-administer cocaine for 10–14 days. Expand
An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats
The view that 1-methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous compound, has considerable potential as a drug for combating substance abuse disease through the attenuation of craving is strongly supported. Expand
REVIEW: New developments in the pharmacotherapy of cocaine abuse
  • A. Preti
  • Psychology, Medicine
  • Addiction biology
  • 2007
Disulfiram, prescribed with active psychosocial therapy, was found to favour higher retention rates and longer abstinence periods from both alcohol and cocaine in polydrug‐abusing patients, and targeting symptoms might improve the effectiveness of the treatment of cocaine abuse and dependence. Expand
Activators of G-protein signaling 3: a drug addiction molecular gateway
  • M. Bowers
  • Biology, Medicine
  • Behavioural pharmacology
  • 2010
This review summarizes data showing that protein expression and signaling through the nonreceptor activator of G-protein signaling 3 (AGS3) are altered by commonly abused substances in rat and in in-vitro addiction models, and investigates the unique role of AGS3. Expand
Drug addiction. Part III. Pharmacotherapy of addiction.
  • J. Vetulani
  • Psychology, Medicine
  • Polish journal of pharmacology
  • 2001
The prospects for developing effective pharmacotherapies against addiction are bright, but ideological and social implications, as well as the conflict of interest with illegal narcotic manufacturers and distributors, may considerably hamper the progress in combating addiction. Expand
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.
It is concluded that hypothesis-based medication development strategies could significantly promote medication discovery for the effective treatment of psychostimulant addiction. Expand
Important role of 3-methoxytyramine in the inhibition of cocaine sensitization by 1-methyl-1,2,3,4-tetrahydroisoquinoline: an in vivo microdialysis study.
The results strongly support the view that 1MeTIQ may have a more general anti-abuse potential, and the extraneuronal metabolite of dopamine, 3-MT, may play a crucial role in its anti-craving effects. Expand
Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development
DA partial agonists, in particular the D3-selective and the D1-like partial agonist, offer a more encouraging profile for novel anti-cocaine medications, and are often less severe and only observed at doses above those that antagonize the effects of cocaine. Expand